Startups

CVERGENX, in collaboration with investigators at the Moffitt Cancer Center, has developed a unique molecular diagnostic assay that identifies differences in tumor radiosensitivity, which allows the appropriate selection of patients most likely to benefit from Radiation Therapy.

We are a start-up company based in Jupiter, Florida and we are focused on the treatment of cancer using novel compound technologies discovered at the Moffitt Cancer Center in Tampa, Florida and exclusively licensed by us from them.

An early-stage medical therapeutics company focused on providing personalized medicine solutions to inform cancer immunotherapy decisions.

A therapeutics company developing Akt inhibitors for treating different malignant tumors including breast, prostate, and ovarian.

MDI offers an investment opportunity difficult to find—access to the high rate of return on investment created by the value inflection point that exists between a medical device’s patent filing and its first sale. It is exactly that segment of a device’s lifecycle that provides the highest rate of value inflection and the best return on investment.

We are dedicated towards improving patient outcomes by developing novel approaches for targeting cell adhesion molecules critical for mediating drug resistance and survival of tumor cells.

A molecular diagnostics company developing Akt and histone phosphorylation tests for predicting response to therapies.

A medical device company developing an improved wide band tourniquet for blood draws.